 Repare Therapeutics Inc NASDAQ: RPTX presented updated data from its ongoing Phase 12 TRESR trial of RP-3500 for solid tumors with specific synthetic-lethal genomic alterations. The data were featured at the AACR Annual Meeting included monotherapy Phase 1 Module 1 results from. 